• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

GLP-1s Like Novo Nordisk’s Ozempic Do Not Increase Thyroid Cancer Risk: Study

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 10, 2024 at 09:52: AM
via GLP-1 receptor agonists—a popular drug class that includes Novo Nordisk’s Ozempic (semaglutide) and Victoza (liraglutide)—do not appear to increase the risk of thyroid cancer, according to a new study published Wednesday in The BMJ.

article source
 

<



Similar threads

cafead
Novo Nordisk’s GLP-1 sales surge, but Q2 earnings disappoint
Replies
0
Views
45
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them
Replies
0
Views
23
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
Replies
0
Views
70
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Riding GLP-1 wave, Novo Nordisk lays out $560M to boost drug production in China
Replies
0
Views
130
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novo Nordisk, Eli Lilly face injury lawsuit from user of popular GLP-1 medicines
Replies
0
Views
176
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote